Precigen quarterly and half year financial results and general business update.

Dr. Sabzevari, PhD, President and CEO of Precigen, participated in a panel discussion titled, The Emerging Cell & Gene Therapy Landscape - From Hope to Reality, hosted by Scott Gottlieb, MD.

A trial-in-progress update on the PRGN-2009 study titled, “Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers,” was presented as a poster presentation (#483) by Charalampos S. Floudas, MD, DMSc, MS, Assistant Research Physician, Genitourinary Malignancies Branch at the Center for Cancer Research at the National Cancer Institute (NCI).

Helen Sabzevari, PhD, President and CEO of Precigen, presented a company overview.

View details

Oral presentation of the AG019 abstract "Lactococcus lactis producing Proinsulin and IL-10 therapy increases Antigen Specific Regulatory T-cells in Monotherapy and in Combination with an anti-CD3 Monoclonal Antibody (Teplizumab) in newly diagnosed T1D patients." The abstract was presented by Kevan Herold, MD, CNH Long Professor of Immunobiology and of Medicine (Endocrinology) at the Yale School of Medicine. 

Helen Sabzevari, PhD, President and CEO, presented at the H.C. Wainwright Virtual Global Life Sciences Conference.